Intercept Pharmaceuticals Accounts Payable

Intercept Pharmaceuticals (ICPT) currently reports a accounts payable of $10M as of September 2023. That compares with $21M in the prior-year period — down 51.8% year over year. Use the charts on this page to explore Intercept Pharmaceuticals's accounts payable history and peer comparisons.

Intercept Pharmaceuticals's accounts payable decreased from $21M to $10M — a 51.8% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intercept Pharmaceuticals reported $10M in accounts payable as of September 2023. That compares with $21M in the prior-year period — down 51.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $10M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intercept Pharmaceuticals, and consider following ICPT for alerts when major investors trade the stock.

Intercept Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $10M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ICPT with unrelated industries.